Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DKK1 | O94907 | 3/20 | 0.61 |
| ▸ | HCRTR1 | O43613 | 13/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 13/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4535227 | 1.00 | DKK1 (0.61) | DKK1HCRTR1HCRTR2CHRNB2CHRNA7 | |
| SCHEMBL3649141 | 1.00 | DKK1 (0.61) | DKK1HCRTR1HCRTR2CHRNB2CHRNA7 | |
| SCHEMBL3649138 | 1.00 | DKK1 (0.61) | DKK1HCRTR1HCRTR2CHRNB2CHRNA7 | |
| SCHEMBL3697784 | 0.92 | DKK1 (0.65) | DKK1HCRTR1HCRTR2CHRNB2CHRNA7 | |
| SCHEMBL6924444 | 0.85 | HCRTR1 (0.58) | HCRTR1HCRTR2CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL3653520 | 0.82 | DKK1 (0.58) | DKK1HCRTR1HCRTR2 | |
| SCHEMBL4529867 | 0.81 | DKK1 (0.70) | DKK1HCRTR1HCRTR2PDE10APIK3CA | |
| SCHEMBL4529870 | 0.81 | DKK1 (0.70) | DKK1HCRTR1HCRTR2PDE10APIK3CA | |
| SCHEMBL4529872 | 0.81 | DKK1 (0.70) | DKK1HCRTR1HCRTR2PDE10APIK3CA | |
| SCHEMBL3652486 | 0.81 | DKK1 (0.69) | DKK1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054392-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054392-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WNT1, CTNNB1, WNT3A | DKK1 9/4885HCRTR1 1120/4885HCRTR2 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.